Press Releases ProSomnus, Inc.

Equities

OSAPQ

US50535E1082

Delayed OTC Markets Other stock markets 09:30:02 2024-06-21 am EDT			5-day change	1st Jan Change
0.01 ^USD	-15.97%		0.00%	-98.98%

May. 24	Joint Reorganization Plan and Disclosure Statement Filed by ProSomnus, Inc.	CI
May. 20	ProSomnus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024, A Joint Meeting of the American Academy of Sleep Medicine and the Sleep Research Society	May. 30	GL
ProSomnus Announces Strong First Quarter 2024 Revenue Growth	May. 16	GL
ProSomnus : Announces Strong First Quarter 2024 Revenue Growth - Form 8-K	May. 16	PU
ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting	May. 13	GL
Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices	May. 09	GL
ProSomnus Sleep Technologies Takes Strategic Action to Position Company for Long-Term Success	May. 08	GL
ProSomnus : Material Agreement - Form 8-K	May. 02	PU
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results	Mar. 26	GL
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call	Mar. 15	AQ
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call	Mar. 15	GL
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea	Feb. 22	GL
ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024	Feb. 20	GL
ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024	Feb. 20	AQ
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA	Jan. 30	GL
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA	Jan. 30	AQ
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices	Jan. 29	GL
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices	Jan. 29	AQ
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea	Jan. 08	GL
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea	Jan. 08	AQ
Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices	Dec. 19	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ProSomnus, Inc.

Equities

OSAPQ

US50535E1082

Press Releases

Filters